This “Adenosine A2B receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Adenosine A2B receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A2BAR activation leads to dissociation of the Gas and Gß? subunits and subsequent activation of the adenylyl cyclases, which in turn hydrolyze intracellular ATP into cyclic AMP (c AMP), which activates protein kinase A (PKA) and many downstream signaling molecules. The Gs-c AMP-PKA axis is an important A2BAR-mediatedsignalingpathway.
A2BAR signaling is a major pathway contributing to cancer cell proliferation and solid tumor growth, angiogenesis and metastasis, and immune suppression. Thus, A2BAR antagonists are potentially a novel anticancer therapy, either in combination with other anticancer drugs or as a mono-therapy.
A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS-mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects.
It is currently in Phase II stage of development and is being developed by Arcus Biosciences.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Adenosine A2B receptor antagonists Understanding
Adenosine A2B receptor antagonists: Overview
Adenosine is generated mainly via the degradation of adenosine 5'-triphosphate (ATP) released under stress conditions, to protect cells and tissues locally. Adenosine and ATP acting at different classes of receptors often have opposite effects in cell proliferation or cell death. ATP and other adenine nucleotides have antitumor effects via the activation of the P2Y1 receptor (P2Y1R) subtype, whereas adenosine induces cancer cell proliferation and growth of many types of tumors via the activation of the A2B adenosine receptor (AR) .A2BAR activation leads to dissociation of the Gas and Gß? subunits and subsequent activation of the adenylyl cyclases, which in turn hydrolyze intracellular ATP into cyclic AMP (c AMP), which activates protein kinase A (PKA) and many downstream signaling molecules. The Gs-c AMP-PKA axis is an important A2BAR-mediatedsignalingpathway.
A2BAR signaling is a major pathway contributing to cancer cell proliferation and solid tumor growth, angiogenesis and metastasis, and immune suppression. Thus, A2BAR antagonists are potentially a novel anticancer therapy, either in combination with other anticancer drugs or as a mono-therapy.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Adenosine A2B receptor antagonists R&D. The therapies under development are focused on novel approaches for Adenosine A2B receptor antagonists.Adenosine A2B receptor antagonists Emerging Drugs Chapters
This segment of the Adenosine A2B receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Adenosine A2B receptor antagonists Emerging Drugs
Etrumadenant: Arcus Biosciences Etrumadenant (AB928), the dual A2a/A2b adenosine receptor antagonist, designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR,respectively.A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS-mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects.
It is currently in Phase II stage of development and is being developed by Arcus Biosciences.
Adenosine A2B receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Adenosine A2B receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:Major Players working on Adenosine A2B receptor antagonists
There are approx. 7+ key companies which are developing the Adenosine A2B receptor antagonists. The companies which have their Adenosine A2B receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Arcus Biosciences.Phases
This report covers around 7+ products under different phases of clinical development like- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Adenosine A2B receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Adenosine A2B receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenosine A2B receptor antagonists therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenosine A2B receptor antagonists drugs.Adenosine A2B receptor antagonists Report Insights
- Adenosine A2B receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Adenosine A2B receptor antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:- How many companies are developing Adenosine A2B receptor antagonists drugs?
- How many Adenosine A2B receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Adenosine A2B receptor antagonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adenosine A2B receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adenosine A2B receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Palobiofarma
- Arcus Biosciences
- Incyte Corporation
- Teon Therapeutics
- Corvus Pharmaceuticals
- Tarus Therapeutics
- AdoRx Therapeutics
Key Products
- PBF-1129
- Etrumadenant
- INCB106385
- TT-702
- CPI-935
- TT-4
This product will be delivered within 2 business days.
Table of Contents
1. Report Introduction2. Adenosine A2B Receptor Antagonist - Overview4. Comparative AnalysisOther product profiles in the detailed report…..Other product profiles in the detailed report…..AppendixReport MethodologyConsulting ServicesDisclaimerAbout the PublisherNote: Certain sections of the table of contents would vary according to the availability of information
3. Pipeline Therapeutics
5. Adenosine A2B Receptor Antagonist Pipeline Products in Clinical Stages
6. Adenosine A2B Receptor Antagonist Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
8. Inactive Pipeline Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
Almirall
Vernalis
Palobiofarma
CV Therapeutics
